Abstract
1. (1-Methyl-5-piperazin-1-yl-3-propyl-1H-pyrazolo[4,3-d]pyrimidin-7-yl)-(5-methyl-pyridin-2-yl)-amine (UK-469,413) was identified as a lead compound in a new medicinal chemistry programme. UK-469,413 had good physicochemical properties and was slowly metabolized by cytochromes P450 in rat and human liver microsomes.
2. In the rat in vivo the compound was rapidly cleared. Subsequent studies showed that UK-469,413 was rapidly acetylated in rat liver cytosol to an N-acetylpiperazine metabolite that was the major circulating metabolite in rat plasma in vivo.
3. Analogues of UK-469,413 containing the unsubstituted piperazine moiety were rapidly acetylated in rat liver cytosol and had high plasma clearance in the rat in vivo. These compounds were also acetylated in human liver cytosol and the N-acetyl metabolite was a major metabolite formed in incubations with cryopreserved human hepatocytes.
4. Using specific inhibitors, correlation analysis and expressed human N-acetyltransferase (NAT) enzymes the compounds were shown to be substrates of the polymorphically expressed NAT-2 isozyme.
5. Further experiments showed that it was possible to make small structural changes to the piperazine group that retained potency but prevented metabolism by NAT.
Acknowledgements
The authors would like to thank all their colleagues at Pfizer Global Research and Development who contributed to the studies discussed in this paper. This study was sponsored by Pfizer Global Research and Development. This paper includes words that are or are asserted to be a proprietary term or trade mark. Their inclusion does not imply they have acquired for legal purposes a non-proprietary or general significance, nor is any other judgement implied concerning its legal status.
Declaration of interest: The authors report no conflicts of interest. The authors alone are responsible for the content and writing of the paper.